UnknownPHASE1, PHASE2NCT00838240

Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia

Studying Acute erythroid leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Principal Investigator: Roel Willemze
EORTC (Phase I) - Leiden University Medical Center, NL
Intervention: clofarabine(drug)
Enrollment: 114 enrolled
Eligibility: 18-60 years · All sexes
Timeline: 2008

Study locations (10)

A.Z. Sint-Jan, Bruges, Belgium
Institut Jules Bordet, Brussels, Belgium
CHU Sart-Tilman, Liège, Belgium
University Hospital Rebro, Zagreb, Croatia
Hôpital Saint Antoine AP-HP, Paris, France
Azienda Ospedallera Universitaria - Policlinico Tor Vergata, Roma, Italy
Univesita Degli Studi "La Sapienza", Roma, Italy
Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
Leiden University Medical Center, Leiden, Netherlands
Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

Collaborators

Gruppo Italiano Malattie EMatologiche dell'Adulto

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00838240 on ClinicalTrials.gov

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →

← Back to all trials